An experimental cocktail with AstraZeneca antibodies manages to reduce severe illness or death in patients not hospitalized with COVID-19, the results of a late-stage study show, said the British drug manufacturer, quoted by WORK.
The drug, called AZD7442, reduced the risk of developing serious COVID-19 or death by 50% in patients who had symptoms for seven days or less, fulfilling the main goal of the study. https://t.co/nHTr9D3oTI
– Rappler (@ rapplerdotcom) October 11, 2021
The drug, called AZD7442, reduced the risk of developing serious COVID-19 or death by 50% in patients who had symptoms for seven days or less, thus fulfilling the main purpose of the study.
“Early intervention with our anti-antibody cocktail can significantly reduce the progression of severe disease, with long-term protection for more than six months,” said Mene Pangalos, executive vice president of biopharmaceutical research and development at AstraZeneca.
The company will discuss the data with the health authorities, AstraZeneca added, but without providing more specific details.
AstraZeneca is also developing a cocktail as a therapy to protect people who do not have a strong enough immune response to COVID-19 vaccines.
Last week, the company requested urgent approval from U.S. regulators for the use of this drug to prevent coronavirus.